- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00229541
Medical In-Patient Rehabilitation in Rheumatoid Arthritis
Medical In-Patient Rehabilitation in Rheumatoid Arthritis: Acceptance and Outcomes in Insurants of Compulsory Health Insurances and Statutory Pension Insurances (VERA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rheumatoid arthritis is the most prevalent inflammatory rheumatic disease. Limited participation of the individual patient accumulates with large amounts of indirect costs for society: About 40 % of the affected patients have to quit their jobs within the first three to four years after disease onset. Nevertheless, the German health care system still seems to lack an adequate supply, particularly in case of medical rehabilitation in early stages of disease. International clinical trials, reviews amd evidence-based guidelines emphasize the importance of an early multimodal multidisciplinary team care as in Germany provided by specialised clinics through three-week in-patient medical rehabilitation programs. The available study explores the efficacy of a counselling interview on an medical in-patient rehabilitation in a randomised controlled design. Exclusively, gainfully employed insurants of compulsory health insurances and statutory pension insurances are included in the study.
Secondary, to avoid the problem of a selection bias caused by recruitment via clinics or doctors, the RCT tests the possibility to recruit potential participants by data of the co-operating health insurances on RA-specific diagnoses of work incapacity, hospital discharge diagnoses, and medical prescriptions within the past 24 months.
Detailed process:
- Recruitment of a potential study population via health insurance data (defined search criteria: ICD-10 diagnoses M05/06/13/79 in case of work disability/hospital discharge, RA-specific medical prescriptions within the past 24 months)
- screening questionnaire to verify in-/exclusion criteria
- selection of eligible insurants (RA-criteria of American College of Rheumatology, clinical expert)
- baseline measurement (e.g. SF-36, RAQoL, FFbH-P, SPE)
- external stratified block by block randomization: intervention group (3- week medical in-patient rehabilitation) vs. control group (usual care)
- follow-up measurement (12 months after baseline)
- data transfer of health insurances and pension insurances
Comparison:
Looking at a 12-months follow-up, the intervention group (3-week medical in-patient rehabilitation) is expected to show significant enhancement in somatic, mental and social medical parameters concerning rheumatoid arthritis compared to a control group receiving usual care.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Luebeck, Germany, 23538
- Institute for Social Medicine, University of Luebeck
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Rheumatoid arthritis / psoriatic arthritis (expert decision, ACR criteria)
- Insurant of co-operating health insurance and pension insurance
- Gainfully employed
- Eligible to receive a medical in-patient rehabilitation
Exclusion Criteria:
- Polyarthritis, inflammatory intestinal diseases and diseases of connective tissue
- Currently work disabled
- Not able / not willing to co-operate
- Medical in-patient rehabilitation within past 48 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IG
intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
|
Counselling and 3-week medical in-patient rehabilitation in IG
|
No Intervention: KG
control group, receives usual care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
work incapacity (incidence, duration)
Time Frame: baseline, 12 months follow-up
|
baseline, 12 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
general health status (SF-36)
Time Frame: baseline, 12 months follow-up
|
baseline, 12 months follow-up
|
Functional capacity (FFbH-P)
Time Frame: baseline, 12 months follow-up
|
baseline, 12 months follow-up
|
Quality of life (RAQoL)
Time Frame: baseline
|
baseline
|
Subjective prognosis of gainful employment (SPE-scale)
Time Frame: baseline, 12 months follow-up
|
baseline, 12 months follow-up
|
Somatization (SCL-90-R)
Time Frame: baseline, 12 months follow-up
|
baseline, 12 months follow-up
|
Depression
Time Frame: baseline, 12 months follow-up
|
baseline, 12 months follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Heiner Raspe, Prof.Dr.Dr., Institute for Social Medicine, University of Luebeck
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FKZ 01GL0306
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Counselling and 3-week medical in-patient rehabilitation
-
University Hospital, LinkoepingCompletedOsteoporosis | Vertebral FractureSweden
-
5 SantéA.E.R.O.B.I.E.; INSERM U1046 Physiologie et médecine expérimentale du cœur...CompletedSleep Apnea, Obstructive | Metabolic SyndromeFrance
-
Yale UniversityAstraZenecaCompletedHeart FailureUnited States
-
University of Illinois at ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of Kansas Medical CenterPatient-Centered Outcomes Research InstituteCompleted
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma US, Inc.CompletedEGFR-Mutant Lung CancerUnited States
-
Norwegian Breast Cancer GroupCompletedBreast NeoplasmNorway
-
Memorial Sloan Kettering Cancer CenterThe City College of New York; Queens Cancer Center of Queens Hospital; New York... and other collaboratorsRecruitingAdvanced CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)CompletedOvarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Vaginal Cancer | Peritoneal Cancer | Uterine CancerUnited States
-
Servier RussiaCompletedMyocardial Infarction | Coronary Artery Disease | Arterial HypertensionRussian Federation